(Total Views: 765)
Posted On: 06/09/2022 12:09:37 PM
Post# of 148892
Long, detailed article published yesterday about the role of chemokine systems in cancer and inflammatory diseases. Leronlimab is listed in the table of clinical trials targeting chemokines and their receptors, although it shows the status as "recruiting" for 3 trials.
Excerpts below are where Leronlimab is mentioned in the article.
Recent studies have shown that inhibition of the CCL5/CCR5 axis by the monoclonal antibody leronlimab could alleviate the symptoms of patients with critical pneumonia. Also, it was observed that the levels of inflammatory molecules such as CCL5, IL-6, and TNF-α in the serum of patients were reduced after anti-CCR5 treatment.
We have described above the seminal function of the CCL5/CCR5 axis on tumor progression in preclinical studies, which can be attenuated by knocking down CCL5, using antibody neutralization, and CCR5 antagonists to block ligand–receptor binding, setting the stage for drugs targeting the CCL5/CCR5 axis to enter clinical trials. Table 2 summarizes clinical trials of several CCR5 antagonists (maraviroc, vicriviroc, AZD5672, and leronlimab) for the treatment of metastatic CRC, advanced breast and pancreatic ductal carcinoma, and Kaposi's sarcoma associated with HIV infection (Table 2).
https://onlinelibrary.wiley.com/doi/full/10.1...nT1BNCTG1g
Excerpts below are where Leronlimab is mentioned in the article.
Recent studies have shown that inhibition of the CCL5/CCR5 axis by the monoclonal antibody leronlimab could alleviate the symptoms of patients with critical pneumonia. Also, it was observed that the levels of inflammatory molecules such as CCL5, IL-6, and TNF-α in the serum of patients were reduced after anti-CCR5 treatment.
We have described above the seminal function of the CCL5/CCR5 axis on tumor progression in preclinical studies, which can be attenuated by knocking down CCL5, using antibody neutralization, and CCR5 antagonists to block ligand–receptor binding, setting the stage for drugs targeting the CCL5/CCR5 axis to enter clinical trials. Table 2 summarizes clinical trials of several CCR5 antagonists (maraviroc, vicriviroc, AZD5672, and leronlimab) for the treatment of metastatic CRC, advanced breast and pancreatic ductal carcinoma, and Kaposi's sarcoma associated with HIV infection (Table 2).
https://onlinelibrary.wiley.com/doi/full/10.1...nT1BNCTG1g
(8)
(0)Scroll down for more posts ▼
